TY - JOUR T1 - Ruxolitinib As a Salvage Therapy for Acute and Chronic Graft-versus-Host Disease in Children and Young Adults: a single institution experience JF - medRxiv DO - 10.1101/2021.10.29.21265670 SP - 2021.10.29.21265670 AU - Melissa Mavers AU - Edna Klinger AU - David C Shyr AU - Ami J Shah AU - Alice Bertaina AU - Sandeep Soni Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/30/2021.10.29.21265670.abstract N2 - Background Ruxolitinib, a Janus kinase (JAK)-1/JAK-2 inhibitor that reduces T-cell activation and proliferation leading to a potent anti-inflammatory effect, was recently approved to treat steroid-refractory acute graft-versus-host disease (aGvHD) and is under study for chronic GvHD (cGvHD). However, there are few reports on its use in pediatric and young adult patients with GvHD.Methods We retrospectively report our single center experience with ruxolitinib in 15 patients aged 11-29 years: 5 patients with steroid refractory/steroid dependent aGvHD and 10 patients with cGvHD who had failed at least one systemic therapy.Results In the aGvHD group, ruxolitinib led to an overall response rate (ORR) of 40% at day 28 and 80% with longer follow-up (complete response, CR 60%), with a median of 21 days (5-74) to achieve a response. In the cGvHD group (9 evaluable patients), we observed an ORR of 67% and a CR of 22%, with a median of 78 days (35-180) to achieve a response. Adverse events included cytopenias, gastrointestinal symptoms, infections, and an allergic reaction attributable to ruxolitinib.Conclusions Overall, our results show that ruxolitinib is an effective salvage therapy for severe GvHD in pediatric and young adult patients. The toxicities noted warrant adequate antimicrobial prophylaxis and close monitoring of blood counts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the NIH (K08 HL151809 to MM) and St. Baldricks Foundation (Scholar Award to MM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Stanford University gave ethical approval for this work (IRB-53278).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors, pending appropriate approval for access to clinical data.JAKJanus KinaseaGvHDAcute Graft-versus-Host DiseasecGvHDChronic Graft-versus-Host DiseaseORROverall Response RateCRComplete ResponseHCTHematopoietic Cell TransplantationSRSteroid-refractorySDSteroid dependencePRPartial ResponseGIGastrointestinalNRNo ResponseTFTreatment Failure ER -